+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Advances in adjuvant therapy of gastrointestinal stromal tumors



Advances in adjuvant therapy of gastrointestinal stromal tumors



Current Oncology Reports 14(4): 327-332



The Gastrointestinal Stromal Tumor (GIST) is the most common sarcoma of the gastrointestinal tract. Major prognostic indices in the evaluation and management of GIST include the size, location and tumor mitotic rate. The discovery of the mutation in the tyrosine kinase receptor c-KIT (CD117) revolutionized the treatment of GIST in the early twenty-first century. Since the first case report of the success of the tyrosine kinase inhibitor (TKI) imatinib, in the treatment of a female patient with metastatic GIST, the paradigm of treatment of this tumor has evolved tremendously. The initial use in metastatic GISTs has progressed to use of the TKI in both the adjuvant and neoadjuvant settings. It is now standard of care for patients with complete resection of primary localized GIST, with high risk of recurrence, to have at least one year of adjuvant imatinib. Recent SSGVXIII study shows that patients benefit from extended duration of therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051396780

Download citation: RISBibTeXText

PMID: 22535506

DOI: 10.1007/s11912-012-0241-0


Related references

Adjuvant therapy of gastrointestinal stromal tumors. Current Opinion in Oncology 24(4): 414-418, 2012

Adjuvant imatinib therapy for gastrointestinal stromal tumors. Journal of Surgical Oncology 104(8): 896-900, 2011

Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. Annals of Gastroenterological Surgery 3(1): 43-49, 2019

Gastrointestinal stromal tumors: risk assessment and adjuvant therapy. Hematology/Oncology Clinics of North America 27(5): 889-904, 2014

The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors. Current Opinion in Oncology 20(4): 428-432, 2008

Recent advances in therapy for gastrointestinal stromal tumors. Current Oncology Reports 9(3): 165-169, 2007

Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors. Molecular Diagnosis & Therapy 17(1): 9-19, 2013

Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib. Anti-Cancer Drugs 23 Suppl: S3-S6, 2012

Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors: Where Is Goldilocks When We Need Her?. JAMA Oncology 2(6): 721-722, 2016

Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. International Journal of Cancer 128(9): 2202-2214, 2011

Local excision with adjuvant imatinib therapy for anorectal gastrointestinal stromal tumors. Techniques in Coloproctology 17(5): 571-574, 2014

Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors. JAMA 307(12): 1312-1314, 2012

Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. International Journal of Cancer 129(11): 2533-2542, 2011

Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States. Annals of Surgical Oncology 19(1): 184-191, 2012

Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy. Journal of Gastrointestinal Cancer 43(4): 547-552, 2013